Business Context and Reporting Period
Kforce Inc. filed a Form 8-K Current Report on March 17, 2012, regarding a material definitive agreement entered into on that date. The company is incorporated in Florida and operates from Tampa, Florida.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow.
- Transaction Value: $50.0 million total cash purchase price.
- Adjustments: Subject to a post-closing working capital adjustment.
- Asset Sold: 100% of the issued and outstanding stock of Kforce Clinical Research, Inc. (KCR), a wholly-owned subsidiary.
Material Changes
The primary material change is the divestiture of the Kforce Clinical Research, Inc. subsidiary. The company entered into a Stock Purchase Agreement to sell this subsidiary to inVentiv Health, Inc. The consummation of the sale is expected to occur at the end of March 2012, contingent upon customary closing conditions.
Outlook, Risks, and Management Commentary
Management announced the agreement via a press release on March 19, 2012. The filing states that, other than the Agreement and related documents, there are no material relationships between Kforce Inc. (including its directors and officers) and the Purchaser. The agreement includes customary representations, warranties, covenants, and indemnification provisions.
Investor Verification Checklist
- Verify the final closing date, as the transaction is contingent on customary conditions.
- Monitor the post-closing working capital adjustment to determine the final cash consideration received.
- Review the impact of the divestiture on future revenue streams and segment reporting in subsequent 10-Q or 10-K filings.
- Confirm the absence of undisclosed material relationships with inVentiv Health, Inc. as stated in the filing.